Alvotech (Alvotech) Institutional Ownership : 1.28% (As of May. 18, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Alvotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alvotech's institutional ownership is 1.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alvotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alvotech's Float Percentage Of Total Shares Outstanding is 31.23%.

Alvotech Institutional Ownership Historical Data

The historical data trend for Alvotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Institutional Ownership Chart

Alvotech Historical Data

The historical data trend for Alvotech can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	0.02	0.02	1.17	1.19	1.21	1.24	1.27	1.28	1.28	1.28

Alvotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Alvotech (Alvotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ALVO:Iceland Z45:Germany

Address

9, rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.